ArticleFrontiers in pharmacology2025

Cadonilimab in combination with chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis.

Zuojuan Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.